Multimeric HSV Vaccine Complexes for Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HSV vaccines have shown poor performance in clinical trials due to their focus on limited antigens, and there is an urgent need for a vaccine that can prevent initial infection and periodic reactivation of Herpes Simplex Virus (HSV), as existing therapies like acyclovir cannot avoid viral reactivation and may lead to resistance.
Innovation Solution
Development of a vaccine composition comprising multimeric complexes of HSV polypeptides such as UL11, UL16, UL21, UL48, UL49, gE, UL31, and UL34, which are co-expressed and purified to form stable complexes that elicit a stronger immune response, potentially preventing HSV infection and reactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a limited number of HSV antigens are used in vaccine composition, then the vaccine development process is simpler, but the immune response is insufficient and clinical performance is poor
Solution Approach 1:
The patent combines multiple HSV antigens (gB, gD, gE, UL49.5, UL35, ICP4, ICP27) into a single vaccine composition that forms multimeric complexes. This merging of multiple antigenic components creates a more comprehensive immune response while maintaining a manageable vaccine formulation structure, directly addressing the contradiction between simplicity and effectiveness.
2Reliability
If acyclovir therapy is used to treat HSV infections, then symptoms are controlled effectively, but the virus can develop resistance through mutations in thymidine kinase or DNA polymerase
Solution Approach 1:
The vaccine provides preliminary immune protection before HSV infection or reactivation occurs. By pre-establishing immunity through vaccination with multiple antigens, the vaccine prevents viral establishment and reactivation, thereby preventing the opportunity for resistance development that occurs with therapeutic antiviral use.
3Reliability
If acyclovir and related precursor drugs are used, then the margin of safety is excellent due to selective activation by viral thymidine kinase, but these drugs cannot prevent periodic viral reactivation from latency
Solution Approach 1:
The vaccine performs preliminary action by establishing immune memory before viral reactivation occurs. The multimeric antigen complexes prime the immune system to recognize and respond to HSV upon reactivation from latency, providing long-term protection that extends beyond the acute treatment window of antiviral drugs.
Data Source
AI summary
The present invention relates to a vaccine composition comprising a multimeric complex of Herpes Simplex Virus (HSV) polypeptides for the treatment or vaccination against HSV. The present invention also relates to a vector comprising a polynucleotide encoding the HSV polypeptides and a host cell comprising the vector. The present invention further comprises a method for producing the vaccine composition.